nach oben

Current Treatment Options in Cardiovascular Medicine

Erschienen in:

01.04.2017 | Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

verfasst von: John W. MacArthur, MD, Amanda N. Steele, BS, Andrew B. Goldstone, MD, Jeffrey E. Cohen, MD, William Hiesinger, MD, Y. Joseph Woo, MD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Opinion statement

Over the past two decades, the field of cardiovascular medicine has seen the rapid development of multiple different modalities for the treatment of ischemic myocardial disease. Most research efforts have focused on strategies aimed at coronary revascularization, with significant technological advances made in percutaneous coronary interventions as well as coronary artery bypass graft surgery. However, recent research efforts have shifted towards ways to address the downstream effects of myocardial infarction on both cellular and molecular levels. To this end, the broad application of injectable hydrogel therapy after myocardial infarction has stimulated tremendous interest. In this article, we will review what hydrogels are, how they can be bioengineered in unique ways to optimize therapeutic potential, and how they can be used as part of a treatment strategy after myocardial infarction.

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44. doi:10.1161/CIR.0b013e31820a55f5.CrossRefPubMed

Jackson BM, Gorman JH, Moainie SL, Guy TS, Narula N, Narula J, et al. Extension of borderzone myocardium in postinfarction dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(6):1160–7. discussion 8-71.CrossRefPubMed

Wenk JF, Klepach D, Lee LC, Zhang Z, Ge L, Tseng EE, et al. First evidence of depressed contractility in the border zone of a human myocardial infarction. Ann Thorac Surg. 2012;93(4):1188–93. doi:10.1016/j.athoracsur.2011.12.066.CrossRefPubMedPubMedCentral

Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev. 2008;37(8):1473–81. doi:10.1039/b713009k.CrossRefPubMed

Yan C, Pochan DJ. Rheological properties of peptide-based hydrogels for biomedical and other applications. Chem Soc Rev. 2010;39(9):3528–40. doi:10.1039/b919449p.CrossRefPubMedPubMedCentral

Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002;54(1):3–12.CrossRefPubMed

Moller L, Krause A, Dahlmann J, Gruh I, Kirschning A, Drager G. Preparation and evaluation of hydrogel-composites from methacrylated hyaluronic acid, alginate, and gelatin for tissue engineering. Int J Artif Organs. 2011;34(2):93–102.CrossRefPubMed

Dorsey SM, McGarvey JR, Wang H, Nikou A, Arama L, Koomalsingh KJ, et al. MRI evaluation of injectable hyaluronic acid-based hydrogel therapy to limit ventricular remodeling after myocardial infarction. Biomaterials. 2015;69:65–75. doi:10.1016/j.biomaterials.2015.08.011.CrossRefPubMedPubMedCentral

Tous E, Weber HM, Lee MH, Koomalsingh KJ, Shuto T, Kondo N, et al. Tunable hydrogel-microsphere composites that modulate local inflammation and collagen bulking. Acta Biomater. 2012;8(9):3218–27. doi:10.1016/j.actbio.2012.05.027.CrossRefPubMedPubMedCentral

10.

Plotkin M, Vaibavi SR, Rufaihah AJ, Nithya V, Wang J, Shachaf Y, et al. The effect of matrix stiffness of injectable hydrogels on the preservation of cardiac function after a heart attack. Biomaterials. 2014;35(5):1429–38. doi:10.1016/j.biomaterials.2013.10.058.CrossRefPubMed

11.

• Rodell CB, MacArthur JW, Dorsey SM, Wade RJ, Wang LL, Woo YJ, et al. Shear-thinning supramolecular hydrogels with secondary autonomous covalent crosslinking to modulate viscoelastic properties in vivo. Adv Funct Mater. 2015;25(4):636–44. doi:10.1002/adfm.201403550. In this manuscript, Rodell et al describe hydrogel chemistry that allows for catheter based delivery techniques in a shear thinning, self healing format.CrossRefPubMed

12.

Wang T, Wu DQ, Jiang XJ, Zhang XZ, Li XY, Zhang JF, et al. Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur J Heart Fail. 2009;11(1):14–9. doi:10.1093/eurjhf/hfn009.CrossRefPubMed

13.

Eckhouse SR, Purcell BP, McGarvey JR, Lobb D, Logdon CB, Doviak H, et al. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med. 2014;6(223):223ra21. doi:10.1126/scitranslmed.3007244.CrossRefPubMedPubMedCentral

14.

Mann DL, Kubo SH, Sabbah HN, Starling RC, Jessup M, Oh JK, et al. Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg. 2012;143(5):1036–42. doi:10.1016/j.jtcvs.2011.06.014.CrossRefPubMed

15.

Costanzo MR, Ivanhoe RJ, Kao A, Anand IS, Bank A, Boehmer J, et al. Prospective evaluation of elastic restraint to lessen the effects of heart failure (PEERLESS-HF) trial. J Card Fail. 2012;18(6):446–58. doi:10.1016/j.cardfail.2012.04.004.CrossRefPubMed

16.

Enomoto Y, Gorman 3rd JH, Moainie SL, Guy TS, Jackson BM, Parish LM, et al. Surgical treatment of ischemic mitral regurgitation might not influence ventricular remodeling. J Thorac Cardiovasc Surg. 2005;129(3):504–11. doi:10.1016/j.jtcvs.2004.09.035.CrossRefPubMed

17.

Pilla JJ, Blom AS, Gorman 3rd JH, Brockman DJ, Affuso J, Parish LM, et al. Early postinfarction ventricular restraint improves borderzone wall thickening dynamics during remodeling. Ann Thorac Surg. 2005;80(6):2257–62. doi:10.1016/j.athoracsur.2005.05.089.CrossRefPubMed

18.

Blom AS, Pilla JJ, Arkles J, Dougherty L, Ryan LP, Gorman 3rd JH, et al. Ventricular restraint prevents infarct expansion and improves borderzone function after myocardial infarction: a study using magnetic resonance imaging, three-dimensional surface modeling, and myocardial tagging. Ann Thorac Surg. 2007;84(6):2004–10. doi:10.1016/j.athoracsur.2007.06.062.CrossRefPubMed

19.

Morita M, Eckert CE, Matsuzaki K, Noma M, Ryan LP, Burdick JA, et al. Modification of infarct material properties limits adverse ventricular remodeling. Ann Thorac Surg. 2011;92(2):617–24. doi:10.1016/j.athoracsur.2011.04.051.CrossRefPubMedPubMedCentral

20.

McGarvey JR, Kondo N, Witschey WR, Takebe M, Aoki C, Burdick JA, et al. Injectable microsphere gel progressively improves global ventricular function, regional contractile strain, and mitral regurgitation after myocardial infarction. Ann Thorac Surg. 2015;99(2):597–603. doi:10.1016/j.athoracsur.2014.09.014.CrossRefPubMed

21.

Kichula ET, Wang H, Dorsey SM, Szczesny SE, Elliott DM, Burdick JA, et al. Experimental and computational investigation of altered mechanical properties in myocardium after hydrogel injection. Ann Biomed Eng. 2014;42(7):1546–56. doi:10.1007/s10439-013-0937-9.CrossRefPubMed

22.

Ifkovits JL, Tous E, Minakawa M, Morita M, Robb JD, Koomalsingh KJ, et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci U S A. 2010;107(25):11507–12. doi:10.1073/pnas.1004097107.CrossRefPubMedPubMedCentral

23.

Tous E, Ifkovits JL, Koomalsingh KJ, Shuto T, Soeda T, Kondo N, et al. Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling. Biomacromolecules. 2011;12(11):4127–35. doi:10.1021/bm201198x.CrossRefPubMedPubMedCentral

24.

Frey N, Linke A, Suselbeck T, Muller-Ehmsen J, Vermeersch P, Schoors D, et al. Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study. Circ Cardiovasc Interv. 2014;7(6):806–12. doi:10.1161/CIRCINTERVENTIONS.114.001478.CrossRefPubMed

25.

Lee LC, Wall ST, Klepach D, Ge L, Zhang Z, Lee RJ, et al. Algisyl-LVR with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart. Int J Cardiol. 2013;168(3):2022–8. doi:10.1016/j.ijcard.2013.01.003.CrossRefPubMedPubMedCentral

26.

• Mann DL, Lee RJ, Coats AJ, Neagoe G, Dragomir D, Pusineri E, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail. 2016;18(3):314–25. doi:10.1002/ejhf.449. This is the first large scale, multi-institutional trial using a hydrogel in heart failure patients.CrossRefPubMed

27.

Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004;44(8):1690–9. doi:10.1016/j.jacc.2004.08.014.CrossRefPubMed

28.

Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23):2775–83. doi:10.1093/eurheartj/ehl388.CrossRefPubMed

29.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110–9. doi:10.1001/jama.2011.1670.CrossRefPubMedPubMedCentral

30.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380–9. doi:10.1001/jama.2012.28726.CrossRefPubMedPubMedCentral

31.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717–26. doi:10.1001/jama.2012.418.CrossRefPubMedPubMedCentral

32.

Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895–904. doi:10.1016/S0140-6736(12)60195-0.CrossRefPubMedPubMedCentral

33.

Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–57. doi:10.1016/S0140-6736(11)61590-0.CrossRefPubMedPubMedCentral

34.

Patel AN, Geffner L, Vina RF, Saslavsky J, Urschel Jr HC, Kormos R, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg. 2005;130(6):1631–8. doi:10.1016/j.jtcvs.2005.07.056.CrossRefPubMed

35.

Li SH, Lai TY, Sun Z, Han M, Moriyama E, Wilson B, et al. Tracking cardiac engraftment and distribution of implanted bone marrow cells: comparing intra-aortic, intravenous, and intramyocardial delivery. J Thorac Cardiovasc Surg. 2009;137(5):1225–33. doi:10.1016/j.jtcvs.2008.11.001. e1.CrossRefPubMed

36.

Li Z, Fan Z, Xu Y, Lo W, Wang X, Niu H, et al. pH-sensitive and thermosensitive hydrogels as stem-cell carriers for cardiac therapy. ACS Appl Mater Interfaces. 2016;8(17):10752–60. doi:10.1021/acsami.6b01374.CrossRefPubMed

37.

Liu Z, Wang H, Wang Y, Lin Q, Yao A, Cao F, et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials. 2012;33(11):3093–106. doi:10.1016/j.biomaterials.2011.12.044.CrossRefPubMed

38.

Matsushita S, Forrester JS, Li C, Sato M, Li Z, Guo X, et al. Administration of cells with thermosensitive hydrogel enhances the functional recovery in ischemic rat heart. J Tissue Eng. 2016;7:2041731416646676. doi:10.1177/2041731416646676.CrossRefPubMedPubMedCentral

39.

Nakajima K, Fujita J, Matsui M, Tohyama S, Tamura N, Kanazawa H, et al. Gelatin hydrogel enhances the engraftment of transplanted cardiomyocytes and angiogenesis to ameliorate cardiac function after myocardial infarction. PLoS One. 2015;10(7):e0133308. doi:10.1371/journal.pone.0133308.CrossRefPubMedPubMedCentral

40.

Wang H, Liu Z, Li D, Guo X, Kasper FK, Duan C, et al. Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction. J Cell Mol Med. 2012;16(6):1310–20. doi:10.1111/j.1582-4934.2011.01409.x.CrossRefPubMedPubMedCentral

41.

Xu Y, Patnaik S, Guo X, Li Z, Lo W, Butler R, et al. Cardiac differentiation of cardiosphere-derived cells in scaffolds mimicking morphology of the cardiac extracellular matrix. Acta Biomater. 2014;10(8):3449–62. doi:10.1016/j.actbio.2014.04.018.CrossRefPubMed

42.

Mathieu E, Lamirault G, Toquet C, Lhommet P, Rederstorff E, Sourice S, et al. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7(12):e51991. doi:10.1371/journal.pone.0051991.CrossRefPubMedPubMedCentral

43.

Roche ET, Hastings CL, Lewin SA, Shvartsman DE, Brudno Y, Vasilyev NV, et al. Comparison of biomaterial delivery vehicles for improving acute retention of stem cells in the infarcted heart. Biomaterials. 2014;35(25):6850–8. doi:10.1016/j.biomaterials.2014.04.114.CrossRefPubMedPubMedCentral

44.

MacArthur Jr JW, Purcell BP, Shudo Y, Cohen JE, Fairman A, Trubelja A, et al. Sustained release of engineered stromal cell-derived factor 1-alpha from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction. Circulation. 2013;128(11 Suppl 1):S79–86. doi:10.1161/CIRCULATIONAHA.112.000343.CrossRefPubMedPubMedCentral

45.

Cohen JE, Purcell BP, MacArthur Jr JW, Mu A, Shudo Y, Patel JB, et al. A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy. Circ Heart Fail. 2014;7(4):619–26. doi:10.1161/CIRCHEARTFAILURE.113.001273.CrossRefPubMedPubMedCentral

46.

Purcell BP, Elser JA, Mu A, Margulies KB, Burdick JA. Synergistic effects of SDF-1alpha chemokine and hyaluronic acid release from degradable hydrogels on directing bone marrow derived cell homing to the myocardium. Biomaterials. 2012;33(31):7849–57. doi:10.1016/j.biomaterials.2012.07.005.CrossRefPubMedPubMedCentral

47.

Reis LA, Chiu LL, Wu J, Feric N, Laschinger C, Momen A, et al. Hydrogels with integrin-binding angiopoietin-1-derived peptide, QHREDGS, for treatment of acute myocardial infarction. Circ Heart Fail. 2015;8(2):333–41. doi:10.1161/CIRCHEARTFAILURE.114.001881.CrossRefPubMed

48.

Zhu H, Jiang X, Li X, Hu M, Wan W, Wen Y, et al. Intramyocardial delivery of VEGF165 via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction. Heart Vessel. 2016;31(6):963–75. doi:10.1007/s00380-015-0710-0.CrossRef

49.

Sonnenberg SB, Rane AA, Liu CJ, Rao N, Agmon G, Suarez S, et al. Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. Biomaterials. 2015;45:56–63. doi:10.1016/j.biomaterials.2014.12.021.CrossRefPubMedPubMedCentral

50.

Projahn D, Simsekyilmaz S, Singh S, Kanzler I, Kramp BK, Langer M, et al. Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction. J Cell Mol Med. 2014;18(5):790–800. doi:10.1111/jcmm.12225.CrossRefPubMedPubMedCentral

51.

Camci-Unal G, Aubin H, Ahari AF, Bae H, Nichol JW, Khademhosseini A. Surface-modified hyaluronic acid hydrogels to capture endothelial progenitor cells. Soft Matter. 2010;6(20):5120–6. doi:10.1039/c0sm00508h.CrossRefPubMedPubMedCentral

52.

Koudstaal S, Bastings MM, Feyen DA, Waring CD, van Slochteren FJ, Dankers PY, et al. Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. J Cardiovasc Transl Res. 2014;7(2):232–41. doi:10.1007/s12265-013-9518-4.CrossRefPubMedPubMedCentral

53.

Hiesinger W, Perez-Aguilar JM, Atluri P, Marotta NA, Frederick JR, Fitzpatrick 3rd JR, et al. Computational protein design to reengineer stromal cell-derived factor-1alpha generates an effective and translatable angiogenic polypeptide analog. Circulation. 2011;124(11 Suppl):S18–26. doi:10.1161/CIRCULATIONAHA.110.009431.CrossRefPubMedPubMedCentral

54.

MacArthur Jr JW, Trubelja A, Shudo Y, Hsiao P, Fairman AS, Yang E, et al. Mathematically engineered stromal cell-derived factor-1alpha stem cell cytokine analog enhances mechanical properties of infarcted myocardium. J Thorac Cardiovasc Surg. 2013;145(1):278–84. doi:10.1016/j.jtcvs.2012.09.080.CrossRefPubMed

55.

Shudo Y, Cohen JE, Macarthur JW, Atluri P, Hsiao PF, Yang EC, et al. Spatially oriented, temporally sequential smooth muscle cell-endothelial progenitor cell bi-level cell sheet neovascularizes ischemic myocardium. Circulation. 2013;128(11 Suppl 1):S59–68. doi:10.1161/CIRCULATIONAHA.112.000293.CrossRefPubMedPubMedCentral

56.

Macarthur Jr JW, Cohen JE, McGarvey JR, Shudo Y, Patel JB, Trubelja A, et al. Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1alpha analog in a translational ovine myocardial infarction model. Circ Res. 2014;114(4):650–9. doi:10.1161/CIRCRESAHA.114.302884.CrossRefPubMed

57.

• Purcell BP, Lobb D, Charati MB, Dorsey SM, Wade RJ, Zellars KN, et al. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014;13(6):653–61. doi:10.1038/nmat3922. This manuscript nicely presents the multidimensionality of hydrogels in biotherapeutics, allowing for targeted delivery with spatiotemporal precision.

58.

Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials. 2009;30(29):5409–16. doi:10.1016/j.biomaterials.2009.06.045.CrossRefPubMedPubMedCentral

59.

Singelyn JM, Sundaramurthy P, Johnson TD, Schup-Magoffin PJ, Hu DP, Faulk DM, et al. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol. 2012;59(8):751–63. doi:10.1016/j.jacc.2011.10.888.CrossRefPubMedPubMedCentral

60.

Seif-Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U, et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med. 2013;5(173):173ra25. doi:10.1126/scitranslmed.3005503.CrossRefPubMed

61.

Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate JA, Cuy JL, et al. Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci U S A. 2010;107(34):15211–6. doi:10.1073/pnas.1006442107.CrossRefPubMedPubMedCentral

62.

Miller JS, Stevens KR, Yang MT, Baker BM, Nguyen DH, Cohen DM, et al. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater. 2012;11(9):768–74. doi:10.1038/nmat3357.CrossRefPubMedPubMedCentral

Titel: Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy
verfasst von: John W. MacArthur, MD
Amanda N. Steele, BS
Andrew B. Goldstone, MD
Jeffrey E. Cohen, MD
William Hiesinger, MD
Y. Joseph Woo, MD
Publikationsdatum: 01.04.2017
Verlag: Springer US
Erschienen in: Current Treatment Options in Cardiovascular Medicine / Ausgabe 4/2017
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI: https://doi.org/10.1007/s11936-017-0530-x

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

Opinion statement

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia

Novel and Advanced Techniques for Complex IVC Filter Retrieval

Updates on Stress Imaging Testing and Myocardial Viability With Advanced Imaging Modalities

Acute Aortic Syndromes: Update in Current Medical Management

Targeting Frailty in Heart Failure

Targeting the Microbiome in Heart Failure

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie